Physician profile
Jay B Nayak
NPI 1427275437
$4,679.72
in general payments reported to CMS, 2019-2025
60 companies · $1,176 in 2025
The $1,176 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $314 · 2021: $531 · 2022: $587 · 2023: $870 · 2024: $861 · 2025: $1,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,854 · Education: $53.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,853.59 |
| Education | $53.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $562.27 | 2019-2025 | |
| Gilead Sciences, INC. | $326.60 | 2021-2025 | Trodelvy |
| Celgene Corporation | $285.73 | 2021-2025 | Reblozyl, Pomalyst, Opdivo |
| Eisai INC. | $230.46 | 2019-2025 | |
| Janssen Biotech, INC. | $227.79 | 2019-2025 | Imbruvica, Talvey, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $211.72 | 2019-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $156.38 | 2020-2025 | Keytruda |
| Abbvie INC. | $141.32 | 2021-2025 | |
| Amgen INC. | $134.13 | 2019-2024 | |
| Seagen INC. | $130.20 | 2019-2023 | Padcev |
| Genentech USA, INC. | $116.63 | 2020-2025 | Phesgo, Tecentriq |
| Daiichi Sankyo INC. | $111.51 | 2020-2024 | Enhertu |
| Pfizer INC. | $102.21 | 2023-2025 | |
| Astellas Pharma US INC | $99.84 | 2023-2025 | Vyloy |
| Galvanize Therapeutics, INC | $98.10 | 2025 | Aliya System |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Nayak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.